医学
生物结合
癌症
药品
抗体-药物偶联物
胃肠道癌
药理学
抗体
癌症研究
药物开发
单克隆抗体
肿瘤科
内科学
免疫学
结直肠癌
纳米技术
材料科学
作者
Davinder Singh,Divya Dheer,Abhilash Samykutty,Ravi Shankar
标识
DOI:10.1016/j.jconrel.2021.10.006
摘要
The antibody-drug conjugates (ADCs) are one the fastest growing biotherapeutics in oncology and are still in their infancy in gastrointestinal (GI) cancer for clinical applications to improve patient survival. The ADC based approach is developed with tumor specific antigen, antibody carrying cytotoxic agents to precisely target and deliver chemotherapeutics at the tumor site. To date, 11 ADCs have been approved by US-FDA, and more than 80 are in the clinical development phase for different oncological indications. However, The ADCs based therapies in GI cancers are still far from having high-efficient clinical outcomes. The limited success of these ADCs and lessons learned from the past are now being used to develop a newer generation of ADC against GI cancers. In this review, we did a comprehensive assessment of the key components of ADCs, including tumor marker, antibody, cytotoxic payload, and linkage strategy, with a focus on technical improvement and some future trends in the pipeline for clinical translation. The various preclinical and clinical ADCs used in gastrointestinal malignancies, their target, composition and bioconjugation, along with preclinical and clinical outcomes, are discussed. The emphasis is also given to new generation ADCs employing novel mAb, payload, linker, and bioconjugation methods are also included.
科研通智能强力驱动
Strongly Powered by AbleSci AI